Mutant protein-tyrosine kinases (PTKs) (PTK)

Mutant protein-tyrosine kinases (PTKs), encompassing both receptor tyrosine kinases (RTKs) and non-receptor PTKs, are enzymes that have undergone genetic alterations leading to constitutive, unregulated signaling (Source: NIH - National Cancer Institute). Under normal physiological conditions, these proteins function as essential mediators of signal transduction, controlling cell growth, metabolism, and survival in response to extracellular stimuli (Source: UniProt Consortium). However, mutations such as point mutations, chromosomal translocations, or gene amplifications can transform these proteins into potent oncogenes that drive the progression of various cancers, including lung, breast, and blood cancers (Source: PubMed - PMCID: PMC4119221). Therapeutic targeting of these mutants is largely achieved through small-molecule tyrosine kinase inhibitors (TKIs) that compete with ATP for binding to the catalytic domain, effectively shutting down the proliferative signals (Source: Nature Reviews Drug Discovery). While these therapies have revolutionized oncology, the emergence of secondary resistance mutations and the potential for off-target toxicities remain significant clinical challenges (Source: PubMed - PMCID: PMC4119221). These targets are central to precision medicine, where patient selection is guided by the specific mutational profile of the tumor (Source: StatPearls - Tyrosine Kinase Inhibitors). The development of next-generation inhibitors continues to address the limitations of first-line treatments, particularly in overcoming gatekeeper mutations (Source: Nature Reviews Drug Discovery).

Other names

Oncogenic tyrosine kinasesMutated receptor tyrosine kinasesActivated protein-tyrosine kinasesMutant RTKsMutant PTKsMutant receptor tyrosine kinases and protein tyrosine kinases

Small-molecule inhibitors typically act as ATP-competitive antagonists, binding to the catalytic domain of the kinase to prevent the phosphorylation of tyrosine residues on downstream signaling substrates, thereby halting oncogenic pathways (Source: Nature Reviews Drug Discovery).